Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > Recent News

View:

Post by SkywalkerofLuke on Apr 26, 2023 4:37pm

Recent News

AGN.c AGNPF is continuing to be a leader in the discovery of new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe.

Highlights of recent news

- Completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT) for stroke and have been approved to move forward

- Received a Notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast)

Considering the stroke treatment market is est. to reach value of $15B by 2027 and more than 1 in 7 (15% of US adults or 37 million people) are estimated to have chronic kidney disease AGN continues to be a leader in large market opportunities.

https://www.algernonpharmaceuticals.com/news-media/news-releases

135